Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: A randomized clinical trial

Chinese Journal of Lung Cancer

Volumn 9, Issue 5, 2006, Pages 443-446

  Pan, Deng ^a   Hou, Mei ^b   Li, Hui ^b   Yu, Ping ^b   Liu, Jianwei ^b  

^a SICHUAN UNIVERSITY   (China)

^b NONE

Author keywords

Cisplatin; Etoposide; Irinotecan; Randomized clinical trial; Small cell lung cancer

Indexed keywords

CISPLATIN; CREATININE; ETOPOSIDE; IRINOTECAN; NITROGEN; UREA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

EID: 33750489104     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Zhou Y, Gwadry FG, Reinhold WC, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res, 2002, 62(6): 1688-1695.
2. Hirose T, Horichi N, Ohmori T, et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer, 2003, 40(3): 333-338.
3. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002, 346(2): 85-91.
4. Comment in. N Engl J Med, 2002, 346(2): 126-128;
5. N Engl J Med, 2002, 346(18): 1414-1415; author reply, 1414-1415.
6. Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy, 2003, 49(4): 200-205.
7. Sun Y, Zhou JC. Manual of Medical Oncology. 4th edition. Beijing: People's Medical Publishing House, 2004. 577-581.
8. Ikuno N, Soda H, Watanabe M, et al. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst, 1995, 87(24): 1876-1883.
9. Comment in: J Natl Cancer Inst, 1996, 88(17): 1240-1241.
10. Takasuna K, Hagiwara T, Hirohashi M, et al. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol, 1998, 42(4): 280-286.
11. Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res, 2001, 7(5): 1136-1141.